Education
About Us
Working with TipRanks
Follow Us
Vyne Therapeutics Inc (VYNE)
:VYNE
Total Valuation
VYNE Therapeutics has a market cap or net worth of $8.28M. The enterprise value is $30.93M.
Market Cap$8.28M
Enterprise Value$30.93M
Share Statistics
VYNE Therapeutics has 25,472,164 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding25,472,164
Owned by Insiders6.31%
Owned by Institutions22.28%
Financial Efficiency
VYNE Therapeutics’s return on equity (ROE) is -0.76 and return on invested capital (ROIC) is -83.63%.
Return on Equity (ROE)-0.76
Return on Assets (ROA)-0.60
Return on Invested Capital (ROIC)-83.63%
Return on Capital Employed (ROCE)-0.84
Revenue Per Employee38.54K
Profits Per Employee-3.06M
Employee Count13
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of VYNE Therapeutics is ―. VYNE Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value2.74
Price to FCF―
Price to Operating Cash Flow-0.38
PEG Ratio―
Income Statement
In the last 12 months, VYNE Therapeutics had revenue of 501.00K and earned -39.83M in profits. Earnings per share was -0.93.
Revenue501.00K
Gross Profit501.00K
Operating Income-43.64M
Pretax Income-39.80M
Net Income-39.83M
EBITDA-43.63M
Earnings Per Share (EPS)-0.93
Cash Flow
In the last 12 months, operating cash flow was -39.77M and capital expenditures -117.00K, giving a free cash flow of -39.89M billion.
Operating Cash Flow-39.77M
Free Cash Flow-39.89M
Free Cash Flow per Share-1.57
Dividends & Yields
VYNE Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.15
52-Week Price Change-82.22%
50-Day Moving Average0.93
200-Day Moving Average1.86
Relative Strength Index (RSI)29.00
Average Volume (3m)3.10M
Important Dates
VYNE Therapeutics upcoming earnings date is Nov 6, 2025, Before Open (Confirmed).
Last Earnings DateAug 14, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend Date―
Financial Position
VYNE Therapeutics as a current ratio of 4.35, with Debt / Equity ratio of 0.14%
Current Ratio4.35
Quick Ratio4.35
Debt to Market Cap0.00
Net Debt to EBITDA0.45
Interest Coverage Ratio0.00
Taxes
In the past 12 months, VYNE Therapeutics has paid 4.00K in taxes.
Income Tax4.00K
Effective Tax Rate>-0.01
Enterprise Valuation
VYNE Therapeutics EV to EBITDA ratio is -2.82, with an EV/FCF ratio of -3.60.
EV to Sales245.20
EV to EBITDA-2.82
EV to Free Cash Flow-3.60
EV to Operating Cash Flow-3.62
Balance Sheet
VYNE Therapeutics has $39.65M in cash and marketable securities with $25.00K in debt, giving a net cash position of -$39.62M billion.
Cash & Marketable Securities$39.65M
Total Debt$25.00K
Net Cash-$39.62M
Net Cash Per Share-$1.56
Tangible Book Value Per Share$1.22
Margins
Gross margin is 100.00%, with operating margin of -8709.98%, and net profit margin of -7950.90%.
Gross Margin100.00%
Operating Margin-8709.98%
Pretax Margin-7944.71%
Net Profit Margin-7950.90%
EBITDA Margin-8709.18%
EBIT Margin-8709.98%
Analyst Forecast
The average price target for VYNE Therapeutics is $1.25, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$1.25
Price Target Upside290.62% Upside
Analyst ConsensusHold
Analyst Count5
Revenue Growth Forecast-2.06%
EPS Growth Forecast64.86%